RCT 80 COVID-19 interstitial pneumonia patients in Italy, 40 treated with probiotics, showing significantly reduced gut inflammatory markers with treatment, and lower ICU admission and mortality, without statistical significance. Bifidobacterium lactis LA 304, lactobacillus salivarius LA 302, and lactobacillus acidophilus LA 201 bid for 10 days.
The immune effects of probiotics are strain-specific.
risk of death, 66.7% lower, RR 0.33, p = 1.00, treatment 0 of 40 (0.0%), control 1 of 40 (2.5%), NNT 40, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
|
risk of ICU admission, 85.7% lower, RR 0.14, p = 0.24, treatment 0 of 40 (0.0%), control 3 of 40 (7.5%), NNT 13, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
|
hospitalization time, 26.3% lower, relative time 0.74, p = 0.52, treatment mean 14.0 (±6.0) n=40, control mean 19.0 (±10.0) n=40.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Saviano et al., 6/28/2022, Randomized Controlled Trial, Italy, peer-reviewed, mean age 59.8, 9 authors.
Contact:
veronica.ojetti@policlinicogemelli.it (corresponding author), angela.saviano@policlinicogemelli.it, alessio.migneco@policlinicogemelli.it, flavia.nasella@gmail.com, francesco.franceschi@policlinicogemelli.it, annalisa.potenza@policlinicogemelli.it, claudia.tarli@policlinicogemelli.it, valentina.siciliano@policlinicogemelli.it, carminepetruzziello@live.it.